A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors
Latest Information Update: 21 Aug 2024
At a glance
- Drugs Lisaftoclax (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 19 Aug 2024 Status changed from recruiting to suspended due to company decision
- 27 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.